Markets

Organon Canada Announces Availability Of NDUVRA To Treat Moderate To Severe Atopic Dermatitis

Sep 28, 2026 · 08:09 AM ET· updated 1h ago

Organon Canada, a global healthcare company, today announces the approval and availability of NDUVRA® (tapinarof cream), 1%, for the topical treatment of moderate to severe atopic dermatitis in adult and pediatric

Why It Matters

Organon Canada got permission to sell a new skin cream called NDUVRA. This shows the company is adding tools to help patients with a common skin problem.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

OGN13.75

+0.01 (+0.11%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.